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Abstract
Electronic nicotine and non-nicotine delivery systems (EN&NNDS) are a heterogeneous class of products 
that use an electrically powered coil to heat and turn a liquid into an aerosol, which is inhaled by the user. 
Throughout the world, governments use different approaches to regulate EN&NNDS in their marketplace. 
This brief provides examples of the three more typical regulatory approaches, including banning the sale of 
EN&NNDS, applying tobacco-control legislation to these products, and creating an elaborate group of specific 
regulations or recommendations related to the sale, marketing, packaging, product regulation, reporting/
notification, taxation and use in workplaces and public places.
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Source: modified after Gravely et al. (2)
Electronic nicotine delivery systems (ENDS) represent a mixed class of products 
that use an electrically powered coil to heat and turn a liquid into an aerosol, 
which is inhaled by the user. The liquid generally is made of propylene glycol, 
glycerol, or a mix of them; it always includes nicotine and may contain flavours. 
When the liquid does not contain nicotine, they are referred to as electronic 
non-nicotine delivery systems (ENNDS). Together, ENDS and ENNDS are 
referred to as EN&NNDS. 
Governments use different approaches to regulate EN&NNDS in their 
marketplace. Four countries have been chosen to depict those different 
approaches: Brazil, Canada, the Republic of Korea and the United Kingdom. 
Canada and the United Kingdom allow the sale of EN&NNDS and regulate 
these products with specific norms applicable to them, but both have particular 
features. Canada has a federal system of government by which the national 
(or federal) level of government regulates some areas of public life through its 
executive, legislative or judiciary branches. Subnational levels of government 
can complement federal regulations related to health or regulate on their 
own. In the United Kingdom, the Government explicitly promotes that smokers 
switch from conventional tobacco to using ENDS to quit smoking. The Republic 
of Korea also allows the sale of EN&NNDS but applies existing regulation for 
conventional tobacco products to ENDS, although not for ENNDS. Brazil bans 
de facto the sale of both ENDS and ENNDS. 
Three of the four countries have a strong tobacco-control environment, indicated 
by implementation at the highest level of achievement of at least four of the six1 
MPOWER measures (1). In the following sections, the prevalence of EN&NNDS 
use and the general regulatory approach towards EN&NNDS is described for 
each country. Annex 1 and Annex 2 present national or federal regulations by 
policy domain and the specific subnational regulations in the case of Canada. 
Fig. 1 compares the prevalence of daily use of ENDS in a sample of combined 
smokers and ex-smokers in each of the four countries described in this document.
1  The six MPOWER measures are: monitor tobacco use and prevention policies, protect people from tobacco smoke, offer 
help to quit tobacco use, warn about the dangers of tobacco (health warnings), enforce bans on tobacco advertising, 
promotion and sponsorship, and raise taxes on tobacco.
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BOX 1.  
EN&NNDS USE IN BRAZIL
The latest data available from 
Brazil are from 2016 and 
cover only the prevalence of 
ENDS use among a sample 
of 1340 adult smokers and 
recent ex-smokers from Rio de 
Janeiro, São Paulo and Porto 
Alegre. At the time, 1% of 
interviewees were using ENDS 
at least once a month and 
0.4% at least daily.
Source: Gravely et al. (2)
Brazil
See Box 1 for a summary of EN&NNDS use in Brazil (2). 
Effectively, Brazil bans EN&NNDS. The marketing, importation and advertising 
of “smoking electronic devices” has been prohibited through the Resolution 
of the Collegiate Board of the National Health Surveillance Agency of Brazil 
(ANVISA) (RDC) 46/2009 (3). Smoking electronic devices include EN&NNDS 
and heated tobacco products (HTPs), but manufacturers seeking to market 
EN&NNDS in Brazil can submit a request for registration of their product 
if they have the necessary background information proving the efficacy, 
effectiveness and safety of the devices. In such cases, ANVISA reviews 
the information provided and decides whether to register the product, and 
therefore allow its marketing. To date, no request has been submitted for 
registration of EN&NNDS. If any is registered, the legislation on tobacco 
control will apply to EN&NNDS and their use will be banned in all indoor 
public places, workplaces and public transport.
ANVISA’s policy for EN&NNDS continues to be to ban them. At the time, 
the agency’s decision was based on the lack of scientific data on the claims 
of these products, but ANVISA considers its position regularly by reviewing 
periodically scientific evidence on the potential health risks and benefits of 
EN&NNDS (in 2016 (4)), technical panels (in 2018 (5)) and public hearings (in 
2019 (6)) with participation from the industry and public health organizations 
(see ANVISA (7) for links to all presentations made in the hearings).
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Canada
BOX 2.  
EN&NNDS USE IN CANADA
In 2017:
•  2.9% and 1.0% of Canadians 
aged 15 and older had used 
EN&NNDS in the past 30 days 
or daily, respectively; 
•  12.2% of current smokers and 
2.4% of non-smokers were 
past 30-day EN&NNDS users;
•  about 64% of adult EN&NNDS 
users reported that the last 
time they used a device, the 
e-liquid contained nicotine, 
despite nicotine-containing 
e-liquids not being approved 
for sale in Canada at that time; 
and 
•  fruit and tobacco were the 
most commonly cited flavours 
of the last-used EN&NNDS. 
Among young people in school 
grades 7–9 in 2016–2017:
•  5.4% had used an EN&NNDS 
product in the past 30 days; 
and 
•  two thirds of current smokers 
had used EN&NNDS in the 
past 30 days, compared 
to approximately 5% of 
non-smokers.
Source: Reid et al. (8).
See Box 2 for a summary of EN&NNDS use in Canada (8).
A federal law, the Tobacco and Vaping Products Act (TVPA) (9), allowed the 
marketing of ENDS only in 2018: the sale of ENNDS was always permitted. 
Regulations of ENDS stemming from the TVPA were not wholly developed 
at federal level when this brief was written. Health Canada nevertheless 
conducted a public consultation on such regulations (10); the comments 
received were summarized (11) and the Government published the proposed 
regulations in December 2019. These are now subject to public comment until 
the end of January 2020 (12). If approved, the regulation will place additional 
controls to: a) further restrict the promotion of vaping products, including 
at point of sale and online; b) require health warnings on advertisements; 
c) prohibit the manufacture of vaping products with certain flavours or 
flavour ingredients; and d) restrict the concentration and delivery of nicotine 
in vaping products.
Current federal legislation considers EN&NNDS that make health claims 
separately from those that do not. If they do, they are governed at federal 
level by the Food and Drugs Act (13) and its regulations, in addition to the 
TVPA. If EN&NNDS do not make health claims, they are governed by the 
Canada Consumer Product Safety Act (14), as amended in 2018, and the 
TVPA of 2018. 
The TVPA aims “to prevent vaping product use from leading to the use of 
tobacco products by young persons and non-users of tobacco products” 
(9). It establishes a national minimum age of sale for vaping products and 
significantly restricts their promotion, including bans on lifestyle advertising 
or promotions that are appealing to young people. 
All e-liquids are also subject to the Consumer Chemicals and Containers 
Regulations of 2001 (15). The Non-smokers’ Health Act addresses where to 
use and where not to use EN&NNDS in federal workplaces (16). Provinces 
have the authority to expand on the law, including where to use EN&NNDS 
or not in venues that are not under federal jurisdiction.
EN&NNDS are not treated like tobacco products under Canadian tax 
legislation. Only the regular general sale tax, which includes a provincial sale 
tax component, presently applies (17).  Two provinces, however, announced 
in 2019 a tax increase on EN&NNDS for 2020. The Government of British 
Columbia will increase the provincial sales tax on EN&NNDS from 7% to 
20% (18). The tax will apply to all EN&NNDS devices, any substance used 
in the device, and parts and accessories. The new regulations in British 
Columbia will also require plain packaging and health warnings for vaping 
products and restrict public advertising in areas frequented by young people. 
The Government of Alberta has introduced a fiscal plan (19) that includes a 
20% tax on the retail sale price of EN&NNDS products in 2020. The tax will 
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apply to all vaping liquids, including cannabis liquids and do-it-yourself vaping 
products sold separately for vaping, such as propylene glycol, vegetable, 
glycerin, nicotine solutions and flavourings, as well as all vaping devices 
and related accessories (20). In both provinces, the rationale cited for the 
tax increase is to curtail the rise of EN&NNDS use among young people. 
Health Canada actively monitors TVPA compliance among individuals and 
corporations. It inspected more than 3000 retail establishments in 2019, 
while tracking online sales and promotion of EN&NNDS and taking action 
where necessary. Health Canada is also undertaking a public education 
campaign through advertising, social media and experiential events in schools 
to increase awareness about the harms and risks associated with vaping 
product use targeted at young Canadians aged 13–18 (21,22).
Annex 1 contains a description of the federal regulation that applies to 
vaping products. Canada is a federal country in which some of its subnational 
jurisdictions, the provinces, have regulated EN&NNDS within their purview. 
Eight of the 12 provinces and territories have such laws on EN&NNDS (see 
Annex 2 for a summary of their provisions).
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The Republic of Korea
BOX 3.  
EN&NNDS USE IN THE 
REPUBLIC OF KOREA
The Korea National Health and 
Nutrition Examination Survey 
estimated in 2017 that the 
prevalence of using EN&NNDS 
at least once a month among 
adults of 19+ years was 2.3%. 
Among young people between 
13 and 18 years, the figure was 
2.7%, according to the Korea 
Youth Risk Behaviour Web-based 
Survey in 2018. 
A study among adult current 
smokers indicated that 5.5% 
used EN&NNDS at least once a 
month and 2.8% on a daily basis.
Sources: Gravely (2); WHO (23); WHO (24).
See Box 3 for a summary of EN&NNDS use in the Republic of Korea (2,23,24). 
In 2007, the Government amended the scope of the Tobacco Business Act 
(25) to apply not only to products manufactured using tobacco leaves, but 
also to those made without using tobacco leaves as the raw materials for 
inhaling, such as ENDS, except when used as medicines or non-pharmaceutical 
drugs as covered in the Pharmaceutical Affairs Act (26). Article 27-2 of 
the enforcement decree (27) of the National Health Promotion Act (28) in 
2017 names ENDS specifically as electronic cigarettes and defines them as 
products “made to cause the same effect as smoking by inhaling nicotine-
containing solution or shredded tobacco into the body through respiratory 
organ with an electronic device.” 
ENDS and HTPs are classified in the Republic of Korea as “electronic tobacco” 
products, so most tobacco-control legislation applies to ENDS and HTPs.
Using ENDS is not allowed where smoking is banned. Smoking is unlawful in 
all parts of indoor health-care and educational facilities, except universities. 
Smoking is also prohibited in designated non-smoking areas of workplaces 
and public places. 
Advertising of ENDS is illegal on TV, radio and billboards and other outdoor 
facilities. Some forms of marketing, such as promotional discounts, are 
also barred. Enforcement has been challenging, however, typified by the 
refusal of British American Tobacco Korea to take down an ad in the form of 
a music video on the grounds that it showcased “an electronic device” and 
not the container that holds the actual nicotine product. At the same time, 
British American Tobacco offered an aggressive 50% discount for its vaping 
devices (29). Other incidents include an ENDS company targeting young 
people through the promotion of a film in online forums for young people 
with the option of winning free tickets to watch the movie, the placement 
of EN&NNDS in films for teenagers and an EN&NNDS company sponsoring 
a community-based youth orchestra (30).
ENDS must carry pictorial health warnings occupying 50% of the main 
surfaces of the package (31). ENDS packaging and advertisements should 
include health-warning text that indicates they contain harmful substances 
such as tobacco-specific nitrosamines and formaldehyde.
ENDS are subject to a tobacco consumption tax of 628 Won (approximately 
US$ 0.5) per mL of nicotine solution (32). They are also subject to other 
taxes and charges (national health promotion, local education and individual 
consumption taxes) in addition to a waste charge of 24 Won per 20 cartridges 
(approximately US$ 0.02) and 10% value added tax (VAT). In total, ENDS are 
taxed at 1799 Won per mL (approximately US$ 1.5) of nicotine liquid (33).
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The epidemic of lung disease related to the use of adulterated e-liquids 
for EN&NNDS in the United States of America in 2019 has prompted the 
Government of the Republic of Korea to initiate specific actions to curb 
the use of these products among young people. The Government is acting 
on four fronts: amendments to legislation, enforcement of existing laws, 
surveillance and education.
The Ministry of Health and Welfare has submitted to the National Assembly 
changes to the legislation to close some loopholes in the definition of tobacco 
classes, which would include novel products and ban some flavours. The 
specifics of these announced changes to the law are not yet clear. Through 
this legislation, the Government will also require vaping manufacturers to 
submit more detailed information on the ingredients and additives of their 
products.
In enforcing existing laws, the Government is focused on reducing illegal 
sales of e-cigarettes, both online and to minors. At the same time, the 
Korean Agency for Technology and Standards is preventing the distribution 
and sale of illegal batteries for safety reasons and local authorities across 
the country are carrying out inspections to enforce smoke-free regulations 
in public places, with a particular focus on the use of ENDS and HTPs (34).
The Government is closely monitoring potential cases of lung diseases that 
may be related to the use of EN&NNDS through the existing consumer 
risk-monitoring system. The Ministry of Health and Welfare is conducting 
a health education campaign aimed at providing information on the health 
risks associated with EN&NNDS and counselling for smokers on how they 
can quit. 
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The United Kingdom 
BOX 4. 
EN&NNDS USE IN THE UNITED 
KINGDOM 
According to the Eurobarometer, 
5.6% of adults used EN&NNDS 
at least once a month in 2017, 
which represented close to 
3 million users. The United 
Kingdom has the highest 
prevalence of current use of 
EN&NNDS in the European 
Union. Between 18% and 20% of 
current smokers in 2017 were 
also EN&NNDS users, while 
around 9% of ex-smokers and 
0.3–0.6% of never-smokers were 
EN&NNDS users. 
Among adults who had ever 
tried EN&NNDS more than 
twice in 2017, 42% indicated that 
they did it to help stop smoking 
entirely. The proportion of use 
of EN&NNDS at least weekly 
among 11–16-year-olds was 
1–3% in 2015–2017, depending 
on the survey. The proportion of 
never smokers of that age who 
used EN&NNDS regularly in 
2015–2017 was 0.1–0.5%.
Sources: House of Commons Science and 
Technology Committee (35); European 
Commission (36).
See Box 4 for a summary of EN&NNDS use in the United Kingdom (35,36).
As of December 2019, the United Kingdom was still part of the European 
Union (EU), so was subject to the European Tobacco Product Directive (TPD) 
(37) that came into effect in May 2016 and was transposed into United 
Kingdom law via the Tobacco and Related Products Regulations of 2016 (38). 
The TPD does not regulate ENDS with medicinal purposes. ENDS and refill 
containers presented as a remedy to get rid of nicotine addiction or restoring, 
correcting or modifying physiological functions in a significant manner, or 
otherwise intended for medical purposes, are subject to Directive 2001/83/
EC of the European Parliament and of the Council of 6 November 2001 on 
the community code relating to medicinal products for human use, Council 
Directive 93/42/EEC of 14 June 1993 concerning medical devices, and 
Regulation (EC) 726/2004 of the European Parliament and of the Council 
of 31 March 2004 (39). 
In the United Kingdom, ENDS under these transposed directives and regulations 
(40–42) fall under the purview of the Medicines and Healthcare Products 
Regulatory Agency (MHRA).
The TPD does not cover ENNDS, which individual EU Member States can 
regulate. ENNDS are regulated in the United Kingdom under the General 
Product Safety Regulations 2005 (43).
The regulation of ENDS with no medicinal purposes in the United Kingdom:
  sets safety standards for e-liquid containers, such as being child- and 
tamper-proof, being protected against breakage and leakage and having 
a mechanism that ensures refilling without leakage;
  limits the volume of liquid receptacles in disposable ENDS, single-use 
cartridges and tanks to less than or equal to (≤) 2 mL; 
  limits the volume of dedicated refill e-liquid containers to ≤ 10 mL and the 
maximum concentration of nicotine per amount of e-liquid to ≤ 20 mg/mL;
  bans the following substances in e-liquids:
 •   additives that create the impression that a tobacco product has a health 
benefit or presents reduced health risks, such as vitamins;
 •   additives that are associated with energy and vitality, such as caffeine 
or taurine; 
 •   additives having colouring properties for emissions; and 
 •   ingredients that pose a risk to human health in heated or unheated 
form (except for nicotine);
  requires devices to deliver a consistent dose of nicotine under normal 
conditions;
  sets labelling requirements such as carrying information on possible 
adverse effects or addictiveness and toxicity, including a list of ingredients;
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  sets warning requirements about the addictiveness of nicotine;
  requires all ENDS and e-liquids to be notified to MHRA before they 
can be sold; by the end of 2017, almost 400 producers had submitted 
information about 32 407 e-liquids (90% of notifications) or devices (10% 
of notifications);
  allows consumers and health-care professionals to report side-effects 
and safety concerns with ENDS or refill containers to MHRA through 
the Yellow Card reporting system; 
  bans the sale and provision of EN&NNDS and e-liquids to persons under 
the age of 18; and 
  bans advertising of ENDS devices and e-liquids on TV, radio, the Internet 
and specific printed publications.
The TPD does not regulate whether to tax ENDS or how. It leaves these 
decisions to individual Member States. EN&NNDS currently are taxed in 
the United Kingdom as a consumer product with a 20% VAT rate. There are 
no specific taxes for EN&NNDS in the United Kingdom. Tobacco products 
are taxed at a higher rate than EN&NNDS, with specific taxes in addition to 
VAT. In the third quarter of 2019, a 10 mL nicotine-containing e-liquid was 
4.3 times more affordable than a 20-cigarette pack of Marlboro (44).
The TPD also does not regulate where ENDS can and cannot be used (ENDS 
aerosol-free areas), with Member States once again at liberty to decide. The 
United Kingdom has not legislated to restrict where EN&NNDS can be used. 
Wales attempted to limit the use of EN&NNDS in some public places, but 
the bill was voted down. An undetermined number of workplaces, public 
places and transportation systems nevertheless have voluntarily banned 
the use of EN&NNDS where smoking is prohibited.  
The context of regulatory efforts in the United Kingdom is characterized by 
an active scientific and technical debate. Discussion has been influenced by 
several reports, specifically those commissioned by Public Health England,2 
the latest of which was published in 2019 (45), and those from the Royal 
College of Physicians in 2016 (46), the British Medical Association in 2018 
(47) and the House of Commons Science and Technology Committee in 2018 
(35). All these reports agree that EN&NNDS are substantially less harmful 
to health than smoking but are not risk-free. They also indicate that evidence 
on the long-term health impact is lacking. They signify or imply that ENDS 
have been beneficial to public health in the United Kingdom and that their 
promotion as a substitute for smoking is therefore likely to generate significant 
health gains. Similarly, they indicate or imply that concerns about the risk of 
EN&NNDS potentially providing a gateway into conventional smoking have 
not materialized in the United Kingdom (36,48).
Several of these reports describe the lack of high-quality research into the 
effectiveness of ENDS as a cessation aid. They nevertheless agree that most 
reported studies demonstrate a positive relationship between ENDS use 
and smoking cessation. The report from the House of Commons Science 
2  Public Health England is an independent executive agency of the Department of Health and Social Care responsible 
for making the public healthier and reducing differences between the health of different groups by promoting healthier 
lifestyles, advising government and supporting action by local government, the National Health Service and the public.
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and Technology Committee (35) recommends that the National Health 
Service (NHS) in England should set a clear central NHS policy on ENDS 
in mental health facilities, allowing ENDS use by patients as the default 
policy unless an NHS trust can show evidence-based reasons for not doing 
so. The Government responded to the report with a command paper which 
broadly accepted the Committee’s recommendations (49). Regarding ENDS 
as cessation aids, Public Heath England indicated that (45):
Combining EC [electronic cigarettes] (the most popular source of support 
used by smokers in the general population), with stop smoking service 
support (the most effective type of support), should be a recommended 
option available to all smokers. 
The National Institute for Health and Care Excellence (NICE)3 recommended 
in March 2018 that health and social services should explain to people who 
smoke and who are using, or interested in using, an ENDS product to quit 
smoking that while these products are not licensed medicines, they are 
regulated, and many people have found them helpful in quitting smoking 
cigarettes. NICE also recommended that people using ENDS should stop 
smoking tobacco entirely because any smoking is harmful. The NHS long-
term plan for England recommends a new universal smoking cessation 
offer for long-term users of specialist mental health and learning disability 
services, which will include the option for smokers to switch to e-cigarettes 
while in inpatient settings. 
The report from the House of Commons Science and Technology Committee 
(35) expressed concerns about some restrictions established by the TPD. The 
Committee signalled that norms on the size of tanks and refill containers, 
the maximum nicotine concentration and advertising were holding back 
their use as a stop-smoking measure, and that these could be changed 
following the United Kingdom’s departure from the EU. The Committee 
also considered that (35):
the level of taxation on smoking-related products should directly correspond 
to the health risks that they present, to encourage less harmful consumption. 
Applying that logic, e-cigarettes should remain the least-taxed and conventional 
cigarettes the most, with heat-not-burn products falling between the two.
Following a consultation, the Committee of Advertising Practice and the 
Broadcast Committee of Advertising Practice announced that they were 
lifting the blanket ban on making health claims in non-broadcast advertising 
for ENDS in media not regulated under the TPD (outdoor advertising, posters 
on public transport, cinemas, leaflets and direct mail). It currently is unclear 
how the new guidance will be applied in practice.
3  NICE is an independent governmental agency that provides national guidance and advice to improve health and social care.
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Conclusions
In 2014, the Conference of the Parties of the WHO Framework Convention 
on Tobacco Control invited Parties to (50):
consider prohibiting or regulating ENDS/ENNDS, including as tobacco products, 
medicinal products, consumer products, or other categories, as appropriate, 
taking into account a high level of protection for human health.
The Secretariat of the Convention reported in 2018 that 77 Parties regulated 
or banned EN&NNDS (51). By the end of 2019, this figure was reported as 
98 (52). 
This brief provides examples of the three more typical regulatory approaches. 
The first is banning the sale of EN&NNDS. Brazil is a case in point, with the 
exception that the existing legislation allows the Government to reconsider the 
decision as soon as a manufacturer presents convincing evidence to support 
change. The second is the Republic of Korea. This country applies most of 
its tobacco-control legislation to EN&NNDS, with some exceptions. Finally, 
Canada and the United Kingdom (the latter as part of the EU) have created 
an elaborate group of specific regulations or recommendations related to the 
sale (including minimum age), advertising, promotion, sponsorship, packaging 
(child-safety packaging, health-warning labelling and trademark), product 
regulation (nicotine volume/concentration, safety/hygiene, ingredients/
flavours), reporting/notification, taxation, and use in workplaces and public 
places of EN&NNDS products. This brief has sought to reflect the regulatory 
approach of the two countries in this category for a range of reasons, which 
includes the different role of subnational jurisdictions in regulating EN&NNDS 
and the fact that Canada tends specifically to regulate some aspects of 
ENNDS while the United Kingdom does not. 
It is hoped that these case studies provide information to regulators and 
public health advocates seeking to explore what kind of EN&NNDS regulatory 
options are available in practice, so far. 
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Policy domain Brazil Canada Republic of Korea United Kingdom
Product 
classification
EN&NNDS are referred to in the legislation (1) as “smoking electronic devices”. 
They are implicitly classified as tobacco products. “Smoking electronic devices” 
also include heated tobacco products.
The Tobacco and Vaping Products Act (2) defines tobacco products as made in 
whole or in part of tobacco, including tobacco leaves, as well as devices necessary 
for the use of such products (such as tobacco-heating devices). However, it defines 
vaping products very loosely as devices emitting an aerosol for human inhalation 
and the substances intended for use with those devices, with or without nicotine. 
Vaping products therefore include zero-nicotine e-liquids.
ENNDS are considered consumer products, while ENDS are classified as tobacco 
products under articles 2 and 3 of the Tobacco Business Act (3). Article 27-2 of 
the enforcement decree of the National Health Promotion Act (4) defines ENDS 
as products “made to cause the same effect as smoking by inhaling nicotine-
contained solution or shredded tobacco into the body through respiratory organ 
with an electronic device.”
Under the European Tobacco Product Directive (TPD) (5) regulatory framework, 
EN&NNDS and ENDS products that do not make any health claim are classified 
as consumer products, while EN&NNDS that make health claims are considered 
medicinal products. Although one ENDS product has been licensed as a medicine 




Pre-marketing notification to the government is not required. Pre-marketing notification to the government is not required. Pre-marketing notification to the government is not required. Producers of all devices and e-liquids that were on the market before May 2016 
had until November 2016 to submit a notification to the Medicines and Healthcare 
Products Regulatory Agency (MHRA) (7). Producers of new devices and e-liquid 
products must submit a notification six months before they intend to put their 
product on the market.
Pre-marketing information must notify toxicological data regarding ingredients 
(including in heated form) and emissions with potential health impact, including 
addictiveness (8). An “ingredient” is any substance or element present in a finished 





Government pre-marketing approval (registration) is mandatory. The National 
Health Surveillance Agency of Brazil (ANVISA) may authorize registration for 
the marketing of any “smoking electronic devices” based on the submission of 
toxicological studies and specific scientific tests to substantiate their efficacy, 
effectiveness and safety.
Government pre-marketing approval is required if a vaping product is marketed 
for a therapeutic purpose.
Government pre-marketing approval is not required. Government pre-marketing approval is only required for EN&NNDS with a 
therapeutic purpose.
Import, sale and 
distribution
The import, sale and distribution of EN&NNDS are banned unless ANVISA has 
previously registered the product. Presently, no manufacturer has submitted 
any product for registration, so none has been registered. Even if registered, 
the sale, supply (even free of charge) and distribution of any electronic smoking 
devices to minors is prohibited.
The sale and supply of EN&NNDS (vaping products in the legislation) to persons 
under 18 or 19 years of age, depending on the province, are banned. One province, 
Nova Scotia, also bans the possession of vaping products by minors.
The manufacture, importation (9) or sale of e-liquids with ≥ 66 mg/mL of nicotine 
is prohibited under section 38 of the Consumer Chemicals and Containers 
Regulations (CCCR), 2001 (10).
Sale of ENDS is prohibited to minors (under 19 years). Such a ban does not apply 
to ENNDS.
Purchase of “nicotine inhaling products” (ENDS and conventional cigarettes) by or 
for persons under the age of 18 has been banned since 1 October 2015 in England and 
Wales and since 1 April 2017 in Scotland (11). Such a ban does not apply to ENNDS.
Retailers in the European Economic Area (EEA) or a Third Country must complete 
the registration process as required by the TPD before making sales of tobacco 
or ENDS (or both) into the United Kingdom. Retailers from the United Kingdom 
only need to register if they are planning to sell directly to consumers in another 
EEA state.
Annex 1
National or federal regulation that applies to 
EN&NNDS
This annex shows specific regulation of electronic nicotine and non-nicotine 
delivery systems (EN&NNDS) by country and policy domain.
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any product for registration, so none has been registered. Even if registered, 
the sale, supply (even free of charge) and distribution of any electronic smoking 
devices to minors is prohibited.
The sale and supply of EN&NNDS (vaping products in the legislation) to persons 
under 18 or 19 years of age, depending on the province, are banned. One province, 
Nova Scotia, also bans the possession of vaping products by minors.
The manufacture, importation (9) or sale of e-liquids with ≥ 66 mg/mL of nicotine 
is prohibited under section 38 of the Consumer Chemicals and Containers 
Regulations (CCCR), 2001 (10).
Sale of ENDS is prohibited to minors (under 19 years). Such a ban does not apply 
to ENNDS.
Purchase of “nicotine inhaling products” (ENDS and conventional cigarettes) by or 
for persons under the age of 18 has been banned since 1 October 2015 in England and 
Wales and since 1 April 2017 in Scotland (11). Such a ban does not apply to ENNDS.
Retailers in the European Economic Area (EEA) or a Third Country must complete 
the registration process as required by the TPD before making sales of tobacco 
or ENDS (or both) into the United Kingdom. Retailers from the United Kingdom 
only need to register if they are planning to sell directly to consumers in another 
EEA state.
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The advertising, promotion and sponsorship of EN&NNDS are banned unless 
ANVISA has previously registered the product. If any are registered, it is 
reasonable to expect that the same regulation will apply than for smoking 
products, whose advertising and promotion is prohibited, with a sole exemption 
granted for the display of the products at the point of sale. There are some 
restrictions on tobacco sponsorship. 
The advertising of e-liquids with ≥ 66 mg/mL of nicotine is prohibited under 
section 38 of the CCCR, 2001 (10). Otherwise, advertising and promotion of 
vaping products are banned if: 
-  they are appealing to persons under 18 years of age or the product has an 
appearance or a function that could make the product appealing to said 
persons; 
-  they are using lifestyle advertising, testimonials or endorsements (including 
the depiction of a person, character or animal, whether real or fictional), 
however displayed or communicated, including through the packaging; 
-  it is likely to create an association between the brand element or the name 
and a person, entity, event, activity or permanent facility (sponsorship) or 
uses, directly or indirectly, a vaping product-related brand element or the 
name of a vaping product manufacturer in the promotional material related 
to a person, entity, event, activity or permanent facility;
-  they are displaying a vaping product-related brand element or the name 
of a vaping product manufacturer on a permanent facility, as part of the 
name of the facility or otherwise, if the facility is used for a sports or 
cultural event or activity;
-  they are presented in a manner that is false, misleading or deceptive;
-  it could cause a person to believe that health benefits may be derived from 
the use of the product or its emissions; and
-  it could discourage tobacco cessation or encourage the resumed use of 
tobacco products.
Advertising of ENDS is illegal on TV, radio and billboards and other outdoor 
supports. Some forms of marketing, such as promotional discounts, are also 
barred.
ENNDS are not explicitly regulated. In this case, advertising and promotion are 
governed by the Consumer Protection from Unfair Trading Regulations, which 
protect consumers from deception or harassment (12).
Advertising and promotion of ENDS with health claims to the general public, 
if approved by the MHRA, could only be legal if considered over-the-counter 
medicines (13).
The following requirements are only applicable to e-liquids, disposable devices 
and cartridges containing nicotine that are not medicinal products:
-  cross-border advertising of ENDS and advertising in broadcast TV and radio 
is prohibited; and 
-  advertising of ENDS is also banned in newspapers, magazines and periodicals, 
commercial classified ads, commercial email and text messaging (unless 
explicitly opted in), marketers’ online activities (except factual information), 
promotional marketing online and online (display) ads in paid-for space, 
paid-for search listings, preferential listings on price-comparison sites, viral 
advertisements, paid social media placements, advertisement features and 
contextually targeted branded content, in-game and in-app advertising, and 
advertisements that are pushed electronically to devices or distributed 
through web widgets, affiliate links and product placement.
E-liquids, disposable devices and cartridges containing nicotine that are not 
medicinal products are allowed in: 
- outdoor advertising, including digital outdoor advertising;
- posters on public transport (not leaving the United Kingdom);
- cinema, direct mail and leaflets;
- private, bespoke correspondence between a marketer and a consumer; 
- media targeted exclusively to the trade;
- advertisements for businesses in non-broadcast media; and
- sponsorship of events that are not across borders.
Any advertising must:
- ensure the ads are socially responsible;
- not target, feature or appeal to children;
- not confuse e-cigarettes with tobacco products;
- not make medicinal claims and take care with health claims; and
- not mislead about product ingredients or where they may be used.
Public Health England believes that “stating that vaping is at least 95% less 
harmful than smoking remains a good way to communicate the large difference 
in relative risk unambiguously so that more smokers are encouraged to make 
the switch from smoking to vaping” (14).
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- outdoor advertising, including digital outdoor advertising;
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harmful than smoking remains a good way to communicate the large difference 
in relative risk unambiguously so that more smokers are encouraged to make 
the switch from smoking to vaping” (14).
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Specific legislation or regulation of the packaging of EN&NNDS does not 
exist at present. 
Packaging
Canada is considering Vaping Products Labelling and Packaging Regulations 
(15). Until the proposed regulations are approved and come into force, the 
following requirements apply: 
-  e-liquids with ≥ 66 mg/mL of nicotine meet the classification of “very 
toxic” under the CCCR, 2001 and are prohibited from manufacture, import, 
advertising or sale under section 38 of the CCCR, 2001; and
-  e-liquids with 10–65 mg/mL of nicotine meet the classification of “toxic” 
and are subject to all applicable requirements under the CCCR, 2001 for 
toxic chemicals; stand-alone containers of vaping substances intended 
for sale at retail are required to be sold in child-resistant containers and 
to be labelled per the applicable CCCR, 2001 requirements, including a 
toxic-hazard symbol on the container’s main display panel.
Health Canada considers that e-liquids with 0.1–9 mg/mL of nicotine are 
potentially toxic when ingested so therefore must adhere to all requirements 
of the CCCR, 2001 for “toxic” products, including the requirements for a 
child-resistant container.
Packaging
No specific legal norm applies to the regulation of packaging of EN&NNDS so far.
Packaging
All nicotine-containing receptacles (disposable devices, cartridges and 
e-liquids boles) must have: child-resistant and tamper-evident packaging; 
protection against breakage and leakage; and a mechanism for ensuring 
refilling without leakage.
The nicotine-containing liquid must be in: a dedicated refill container not 
exceeding a volume of 10 mL; a disposable electronic cigarette; or a single-use 
cartridge or tank that does not exceed a volume of 2 mL.
Labelling requirements
Specific legislation or regulation of the labelling of EN&NNDS does not exist at 
present. However, if any EN&NNDS is registered, it is reasonable to assume that 
the tobacco product regulation for labelling would apply, including mandatory 
pictorial health warning occupying 50% of the main surfaces of the packaging.
Labelling requirements
Vaping products must carry the following warning: “Nicotine is highly addictive” 
(16).
Labelling requirements
ENDS must carry pictorial health warnings occupying 50% of the main surfaces 
of the package.
Labelling requirements
The pack must have:
-  a health warning: “This product contains nicotine which is a highly addictive 
substance”; the text must be prominent in black on a white background 
covering 30% of the area on the front and back of the unit packet and any 
container pack;
-  a list of ingredients in the liquid where they are used in quantities of 0.1% 
or more;
- nicotine content and delivery per dose;
- batch number; and
- recommendation to keep the product out of reach of children.
The accompanying leaflet (unless included on the pack) must have instructions 
for use and storage, including instructions for refilling where appropriate. 
The MHRA advises that the information should include appropriate advice on 
product storage, particularly on how to ensure the battery does not malfunction, 
contraindications, warnings for specific risk groups and possible adverse effects, 
addictiveness and toxicity, and contact details of the producer, including a 
contact within the European Union (EU).
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Specific legislation or regulation of the packaging of EN&NNDS does not 
exist at present. 
Packaging
Canada is considering Vaping Products Labelling and Packaging Regulations 
(15). Until the proposed regulations are approved and come into force, the 
following requirements apply: 
-  e-liquids with ≥ 66 mg/mL of nicotine meet the classification of “very 
toxic” under the CCCR, 2001 and are prohibited from manufacture, import, 
advertising or sale under section 38 of the CCCR, 2001; and
-  e-liquids with 10–65 mg/mL of nicotine meet the classification of “toxic” 
and are subject to all applicable requirements under the CCCR, 2001 for 
toxic chemicals; stand-alone containers of vaping substances intended 
for sale at retail are required to be sold in child-resistant containers and 
to be labelled per the applicable CCCR, 2001 requirements, including a 
toxic-hazard symbol on the container’s main display panel.
Health Canada considers that e-liquids with 0.1–9 mg/mL of nicotine are 
potentially toxic when ingested so therefore must adhere to all requirements 
of the CCCR, 2001 for “toxic” products, including the requirements for a 
child-resistant container.
Packaging
No specific legal norm applies to the regulation of packaging of EN&NNDS so far.
Packaging
All nicotine-containing receptacles (disposable devices, cartridges and 
e-liquids boles) must have: child-resistant and tamper-evident packaging; 
protection against breakage and leakage; and a mechanism for ensuring 
refilling without leakage.
The nicotine-containing liquid must be in: a dedicated refill container not 
exceeding a volume of 10 mL; a disposable electronic cigarette; or a single-use 
cartridge or tank that does not exceed a volume of 2 mL.
Labelling requirements
Specific legislation or regulation of the labelling of EN&NNDS does not exist at 
present. However, if any EN&NNDS is registered, it is reasonable to assume that 
the tobacco product regulation for labelling would apply, including mandatory 
pictorial health warning occupying 50% of the main surfaces of the packaging.
Labelling requirements
Vaping products must carry the following warning: “Nicotine is highly addictive” 
(16).
Labelling requirements
ENDS must carry pictorial health warnings occupying 50% of the main surfaces 
of the package.
Labelling requirements
The pack must have:
-  a health warning: “This product contains nicotine which is a highly addictive 
substance”; the text must be prominent in black on a white background 
covering 30% of the area on the front and back of the unit packet and any 
container pack;
-  a list of ingredients in the liquid where they are used in quantities of 0.1% 
or more;
- nicotine content and delivery per dose;
- batch number; and
- recommendation to keep the product out of reach of children.
The accompanying leaflet (unless included on the pack) must have instructions 
for use and storage, including instructions for refilling where appropriate. 
The MHRA advises that the information should include appropriate advice on 
product storage, particularly on how to ensure the battery does not malfunction, 
contraindications, warnings for specific risk groups and possible adverse effects, 
addictiveness and toxicity, and contact details of the producer, including a 
contact within the European Union (EU).
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Policy domain Brazil Canada Republic of Korea United Kingdom
Product regulation 
of contents and 
emissions
No specific legal norm applies to the regulation of the contents and emissions 
of EN&NNDS so far, but no EN&NNDS have yet been registered for marketing.
All additives that enhance the flavour and taste of tobacco products to make 
them more attractive are banned (17). It is likely that such a ban would apply 
to EN&NNDS if any such products are registered. 
All characterizing flavours are banned for tobacco products (17). It is likely 
that such a ban would apply to EN&NNDS, if any such products are registered.
Manufacturers of vaping devices are strongly encouraged (but not legally 
required) to certify their products to standard ANSI/CAN/UL 8139 on Electrical 
Systems of Electronic Cigarettes and Vaping Devices and to use lithium-ion 
batteries that meet standard CAN/CSA-E62133 or equivalent. Chargers provided 
with the product should be certified to the applicable Canadian national 
standard by a certification body accredited by the Standards Council of Canada.
The diluents used in vaping liquids should be within the specifications of 
an accepted pharmacopoeia, so solvents of known human toxicity, such as 
ethylene glycol or diethylene glycol, should not be used. 
“Ingredient” means any substance used in the manufacture of a tobacco 
product, vaping product or their components, including any substance used 
in the manufacture of that substance, and, in respect of a tobacco product, 
also includes tobacco leaves.
Additives prohibited are: amino acids, caffeine, colouring agents, essential fatty 
acids glucuronolactone, probiotics, taurine, vitamins and mineral nutrients.
Emissions are not explicitly regulated. However, Health Canada recommends 
that the generation of harmful emissions due to thermal decomposition of 
e-liquids should be as low as reasonably achievable.
It is recommended, but not legally required, that all flavourings added to vaping 
liquids should be of food-grade or higher purity and that substances with known 
inhalation risks (such as diacetyl and 2,3-pentanedione) should not be used in 
flavourings. The following flavours are legally banned: confectionery, dessert, 
cannabis, soft drink and energy drink.
No specific legal norm applies to the regulation of the contents and emissions 
of EN&NNDS so far.
Additives are not explicitly regulated. 
Flavourings can be used but not advertised according to article 9-3 of the 
National Health Promotion Act (4).
E-liquids without nicotine, whether in disposable devices or separate containers, 
are regulated under General Product Safety Regulations (18). A product 
is considered safe if it conforms to: a) a specific health and safety rule of 
part of the United Kingdom, in the absence of a United Kingdom law; b) a 
voluntary national standard of the United Kingdom giving effect to an official 
European standard; or c) otherwise conforms to other specified standards or 
recommendations, including product safety codes of good practice in the 
sector concerned, and reasonable consumer expectations concerning safety. 
The assessment of safety is made regarding the risks and categories of risk 
covered by the specified requirements of conformity.
Nicotine e-liquid ingredients:
- must be of high purity
- may not pose a risk to human health in a heated or unheated form.
The maximum nicotine concentration in e-liquid is 20 mg/mL.
Additives prohibited are: vitamins or other additives that create the impression 
that they have a health benefit or present reduced health risks; caffeine, taurine 
or other additives and stimulant compounds that are associated with energy 
and vitality; and additives that have colouring effects on emissions.
All other additives are restricted to quantities that do not increase, to a significant 
or measurable degree, the toxicity, addictiveness or carcinogenic, mutagenic 
or reprotoxic properties of the product when it is consumed.
Emissions are not specifically regulated.
Flavours are not specifically regulated.
Taxation No specific legal norm applies to the regulation of the taxation of EN&NNDS 
so far, but no EN&NNDS have yet been registered for marketing.
Only the regular general sale tax applies to EN&NNDS. ENDS are subject to several taxes and charges (national health promotion, 
tobacco consumption, local education and individual consumption taxes) 
proportional to 1 799 Won/mL (≈ US$ 1.5) nicotine liquid; also there is a waste 
charge of 24 won/20 cartridges (≈ US$ 0.02) and a 10% value added tax (VAT) (19).
EN&NNDS are taxed with a VAT rate of 20%.
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Policy domain Brazil Canada Republic of Korea United Kingdom
Product regulation 
of contents and 
emissions
No specific legal norm applies to the regulation of the contents and emissions 
of EN&NNDS so far, but no EN&NNDS have yet been registered for marketing.
All additives that enhance the flavour and taste of tobacco products to make 
them more attractive are banned (17). It is likely that such a ban would apply 
to EN&NNDS if any such products are registered. 
All characterizing flavours are banned for tobacco products (17). It is likely 
that such a ban would apply to EN&NNDS, if any such products are registered.
Manufacturers of vaping devices are strongly encouraged (but not legally 
required) to certify their products to standard ANSI/CAN/UL 8139 on Electrical 
Systems of Electronic Cigarettes and Vaping Devices and to use lithium-ion 
batteries that meet standard CAN/CSA-E62133 or equivalent. Chargers provided 
with the product should be certified to the applicable Canadian national 
standard by a certification body accredited by the Standards Council of Canada.
The diluents used in vaping liquids should be within the specifications of 
an accepted pharmacopoeia, so solvents of known human toxicity, such as 
ethylene glycol or diethylene glycol, should not be used. 
“Ingredient” means any substance used in the manufacture of a tobacco 
product, vaping product or their components, including any substance used 
in the manufacture of that substance, and, in respect of a tobacco product, 
also includes tobacco leaves.
Additives prohibited are: amino acids, caffeine, colouring agents, essential fatty 
acids glucuronolactone, probiotics, taurine, vitamins and mineral nutrients.
Emissions are not explicitly regulated. However, Health Canada recommends 
that the generation of harmful emissions due to thermal decomposition of 
e-liquids should be as low as reasonably achievable.
It is recommended, but not legally required, that all flavourings added to vaping 
liquids should be of food-grade or higher purity and that substances with known 
inhalation risks (such as diacetyl and 2,3-pentanedione) should not be used in 
flavourings. The following flavours are legally banned: confectionery, dessert, 
cannabis, soft drink and energy drink.
No specific legal norm applies to the regulation of the contents and emissions 
of EN&NNDS so far.
Additives are not explicitly regulated. 
Flavourings can be used but not advertised according to article 9-3 of the 
National Health Promotion Act (4).
E-liquids without nicotine, whether in disposable devices or separate containers, 
are regulated under General Product Safety Regulations (18). A product 
is considered safe if it conforms to: a) a specific health and safety rule of 
part of the United Kingdom, in the absence of a United Kingdom law; b) a 
voluntary national standard of the United Kingdom giving effect to an official 
European standard; or c) otherwise conforms to other specified standards or 
recommendations, including product safety codes of good practice in the 
sector concerned, and reasonable consumer expectations concerning safety. 
The assessment of safety is made regarding the risks and categories of risk 
covered by the specified requirements of conformity.
Nicotine e-liquid ingredients:
- must be of high purity
- may not pose a risk to human health in a heated or unheated form.
The maximum nicotine concentration in e-liquid is 20 mg/mL.
Additives prohibited are: vitamins or other additives that create the impression 
that they have a health benefit or present reduced health risks; caffeine, taurine 
or other additives and stimulant compounds that are associated with energy 
and vitality; and additives that have colouring effects on emissions.
All other additives are restricted to quantities that do not increase, to a significant 
or measurable degree, the toxicity, addictiveness or carcinogenic, mutagenic 
or reprotoxic properties of the product when it is consumed.
Emissions are not specifically regulated.
Flavours are not specifically regulated.
Taxation No specific legal norm applies to the regulation of the taxation of EN&NNDS 
so far, but no EN&NNDS have yet been registered for marketing.
Only the regular general sale tax applies to EN&NNDS. ENDS are subject to several taxes and charges (national health promotion, 
tobacco consumption, local education and individual consumption taxes) 
proportional to 1 799 Won/mL (≈ US$ 1.5) nicotine liquid; also there is a waste 
charge of 24 won/20 cartridges (≈ US$ 0.02) and a 10% value added tax (VAT) (19).
EN&NNDS are taxed with a VAT rate of 20%.
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Policy domain Brazil Canada Republic of Korea United Kingdom
Use in indoor  
places
The use of EN&NNDS is banned in all enclosed common areas, including aircraft 
and public transportation. An enclosed common area is defined as a public 
or private place, accessible to the general public or for common use, totally 
or partially enclosed on any of its sides by a wall, partition, roof, awning or 
covering, whether of a permanent or temporary nature (20).
The Non-smokers’ Health Act (21) bans indoor use of EN&NNDS in federally 
regulated workplaces, such as banks, ferries, passenger aircraft and federal 
government offices. Most provinces have banned their use where tobacco 
use is banned.
The use of ENDS, but not ENNDS, is banned where smoking is banned, and is 
completely banned in health-care facilities and educational facilities except 
universities. In all other public places and workplaces, smoking and ENDS use 
is banned only in designated no-smoking areas.
There is no blanket legal requirement regulating the use of ENDS or ENNDS in 
workplaces and public spaces. The owner or manager of each venue may decide 
to apply restrictions on a private basis. Although there are no official statistics, 
it seems that most hospitals and transportation have banned vaping indoors. 
Vaping on a plane is strictly not allowed by the companies as per International 
Air Transport Association recommendations (22).
Public Health England issued guidance on the use of EN&NNDS in public 
places and workplaces that emphasizes the distinction between smoking 
and vaping. The guidance states that “a more enabling approach to vaping 
may be appropriate to make it an easier choice than smoking” (23). It also 
recommends that policies be based on evidence of harm to bystanders and 
risk assessments be informed by evidence. The guidance indicates that the 
risk to the health of bystanders from second-hand aerosol is extremely low and 





The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
Surveillance and 
monitoring
No specific legal norm applies to the regulation of the surveillance and 
monitoring of EN&NNDS so far, but no EN&NNDS have yet been registered for 
marketing. In case of irregularities, such as the commercialization, advertising 
and illegal importation of these products, complaints may be lodged through 
ANVISA’s service channels.
Under the Canada Consumer Product Safety Act (CCPSA), sellers, distributors, 
importers, manufacturers and suppliers in general of vaping products for 
commercial purposes must report any health or safety incidents involving 
one such product to Health Canada and the supplier of said product (24). 
Depending on the type, the incident must be reported within two or 10 days 
after the day on which those required to report become aware of the incident.
Any person who manufactures, imports, advertises, sells or tests a vaping product 
for commercial purposes must prepare and maintain documents indicating 
whom they obtained the product from or to whom they sold it, among other 
data. They are required to submit records upon request of the Government. The 
purpose of this requirement is to help improve the traceability of noncompliant 
products through the supply chain if dangers must be addressed (25). Under 
the CCPSA, Health Canada has the power to order recalls and other measures 
and order tests or studies on a product. 
Enforcement actions taken by Health Canada on noncompliant products depend 
on the degree of risk associated with noncompliance.
No legal norm applies to the regulation of the surveillance and monitoring 
of EN&NNDS specifically, but the Government is closely monitoring cases of 
lung diseases potentially related to the use of EN&NNDS through the existing 
consumer risk-monitoring system (26).
Consumers and health-care professionals can report both side-effects and 
product safety concerns to the MHRA through the Yellow Card scheme. 
This scheme records suspected adverse reactions to medicines from health 
professionals, manufacturers or members of the public. It includes ENDS 
and e-liquids. A total of 37 reports were received with a suspected adverse 
reaction to electronic cigarettes between 1 January 2015 and 20 October 2017, 
and 263 reports associated with a suspected adverse drug reaction to nicotine 
replacement therapy were received during the same reporting period. The most 
commonly reported adverse reaction related to gastrointestinal disturbance 
and respiratory problems.
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Policy domain Brazil Canada Republic of Korea United Kingdom
Use in indoor  
places
The use of EN&NNDS is banned in all enclosed common areas, including aircraft 
and public transportation. An enclosed common area is defined as a public 
or private place, accessible to the general public or for common use, totally 
or partially enclosed on any of its sides by a wall, partition, roof, awning or 
covering, whether of a permanent or temporary nature (20).
The Non-smokers’ Health Act (21) bans indoor use of EN&NNDS in federally 
regulated workplaces, such as banks, ferries, passenger aircraft and federal 
government offices. Most provinces have banned their use where tobacco 
use is banned.
The use of ENDS, but not ENNDS, is banned where smoking is banned, and is 
completely banned in health-care facilities and educational facilities except 
universities. In all other public places and workplaces, smoking and ENDS use 
is banned only in designated no-smoking areas.
There is no blanket legal requirement regulating the use of ENDS or ENNDS in 
workplaces and public spaces. The owner or manager of each venue may decide 
to apply restrictions on a private basis. Although there are no official statistics, 
it seems that most hospitals and transportation have banned vaping indoors. 
Vaping on a plane is strictly not allowed by the companies as per International 
Air Transport Association recommendations (22).
Public Health England issued guidance on the use of EN&NNDS in public 
places and workplaces that emphasizes the distinction between smoking 
and vaping. The guidance states that “a more enabling approach to vaping 
may be appropriate to make it an easier choice than smoking” (23). It also 
recommends that policies be based on evidence of harm to bystanders and 
risk assessments be informed by evidence. The guidance indicates that the 
risk to the health of bystanders from second-hand aerosol is extremely low and 





The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
The protection of public health from commercial interest from the EN&NNDS 
industry is not explicitly regulated.
Surveillance and 
monitoring
No specific legal norm applies to the regulation of the surveillance and 
monitoring of EN&NNDS so far, but no EN&NNDS have yet been registered for 
marketing. In case of irregularities, such as the commercialization, advertising 
and illegal importation of these products, complaints may be lodged through 
ANVISA’s service channels.
Under the Canada Consumer Product Safety Act (CCPSA), sellers, distributors, 
importers, manufacturers and suppliers in general of vaping products for 
commercial purposes must report any health or safety incidents involving 
one such product to Health Canada and the supplier of said product (24). 
Depending on the type, the incident must be reported within two or 10 days 
after the day on which those required to report become aware of the incident.
Any person who manufactures, imports, advertises, sells or tests a vaping product 
for commercial purposes must prepare and maintain documents indicating 
whom they obtained the product from or to whom they sold it, among other 
data. They are required to submit records upon request of the Government. The 
purpose of this requirement is to help improve the traceability of noncompliant 
products through the supply chain if dangers must be addressed (25). Under 
the CCPSA, Health Canada has the power to order recalls and other measures 
and order tests or studies on a product. 
Enforcement actions taken by Health Canada on noncompliant products depend 
on the degree of risk associated with noncompliance.
No legal norm applies to the regulation of the surveillance and monitoring 
of EN&NNDS specifically, but the Government is closely monitoring cases of 
lung diseases potentially related to the use of EN&NNDS through the existing 
consumer risk-monitoring system (26).
Consumers and health-care professionals can report both side-effects and 
product safety concerns to the MHRA through the Yellow Card scheme. 
This scheme records suspected adverse reactions to medicines from health 
professionals, manufacturers or members of the public. It includes ENDS 
and e-liquids. A total of 37 reports were received with a suspected adverse 
reaction to electronic cigarettes between 1 January 2015 and 20 October 2017, 
and 263 reports associated with a suspected adverse drug reaction to nicotine 
replacement therapy were received during the same reporting period. The most 
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Additional regulatory requirements by the 
provincial jurisdictions of Canada
This annex shows the specific regulation of electronic nicotine and non-
nicotine delivery systems (EN&NNDS), by Canadian province.
Province Applicable law Main provisions
British Columbia Tobacco and Vapour Products 
Control Act. Date in effect: 1 
September 2016 (1)
Under this law, the following are banned:
-  EN&NNDS use in all enclosed public spaces, including all public and private school grounds, workplaces 
and health-care facilities other than in designated areas; 
- sale and supply to minors (under 19);
- sales wherever tobacco sales are banned;
-  any promotion in stores except at point of sale (POS) showing availability and price, including duty-free shops; 
- all POS displays except at POS where minors are not permitted to enter; and 
- vending machines in adult-only venues, including duty-free shops.
Manitoba The Non-Smokers Health 
Protection and Vapour Products 
Act. Royal assent received: 5 
November 2015 (2)
Under this law, the following are banned: 
-  EN&NNDS use in enclosed public places and other places where smoking is presently prohibited, including 
workplaces, and work vehicles with more than one occupant (the following places are exempted from 
the ban to use EN&NNDS: where EN&NNDS are predominately sold and in designated smoking/vaping 
rooms in hotels and group living facilities); 
- EN&NNDS advertising and promotion as applicable to tobacco products; and
- sale and supply to minors (under 18).
New Brunswick Smoke-free Places Act, 2011. 
Tobacco and Electronic Cigarette 
Sales Act. As amended, date in 
effect: 10 November 2018 (3) 
Provisions of the Act include the following bans:
-  EN&NNDS use where smoking is prohibited, including enclosed public spaces, workplaces, restaurants 
and bars, and vehicles when an individual under the age of 16 is present (there are exemptions for some 
hotel rooms and private residences);
- sale and supply to minors (under 19);
- sales of EN&NNDS wherever tobacco sales are banned; and 
- indoor and outdoor advertising and promotional materials, even within vape shops.
Newfoundland and 
Labrador
Smoke-Free Environment Act (as 
amended) (4), Tobacco and Vapour 
Products Control Act (as amended) 
(5). Date in effect: 17 October 2018 
The following are banned: 
- sale to minors;
- sale wherever tobacco sales are banned;
- POS promotion, products and promotional materials (cannot be visible inside or outside the shop);
- restrictions on signage inside shops; and
- vape shops are allowed to operate if the only business conducted is the sale of vaping products.
Treatment: treats EN&NNDS the same as combustible tobacco cigarettes, prohibiting the use of EN&NNDS 
in any place to which the public customarily has access, including workplaces, private clubs, licensed 
restaurants, bus shelters, and health-care and educational facilities.
Young people: prohibits the use of EN&NNDS in motor vehicles when occupied by a person under the age 
of 16 and prohibits the sale of EN&NNDS and other vaping products to persons under the age of 19.
Communications and advertising: there currently are no restrictions on EN&NNDS advertising. Vape shops 
can provide consumers with testimonials and health information regarding vaping.
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Province Applicable law Main provisions
British Columbia Tobacco and Vapour Products 
Control Act. Date in effect: 1 
September 2016 (1)
Under this law, the following are banned:
-  EN&NNDS use in all enclosed public spaces, including all public and private school grounds, workplaces 
and health-care facilities other than in designated areas; 
- sale and supply to minors (under 19);
- sales wherever tobacco sales are banned;
-  any promotion in stores except at point of sale (POS) showing availability and price, including duty-free shops; 
- all POS displays except at POS where minors are not permitted to enter; and 
- vending machines in adult-only venues, including duty-free shops.
Manitoba The Non-Smokers Health 
Protection and Vapour Products 
Act. Royal assent received: 5 
November 2015 (2)
Under this law, the following are banned: 
-  EN&NNDS use in enclosed public places and other places where smoking is presently prohibited, including 
workplaces, and work vehicles with more than one occupant (the following places are exempted from 
the ban to use EN&NNDS: where EN&NNDS are predominately sold and in designated smoking/vaping 
rooms in hotels and group living facilities); 
- EN&NNDS advertising and promotion as applicable to tobacco products; and
- sale and supply to minors (under 18).
New Brunswick Smoke-free Places Act, 2011. 
Tobacco and Electronic Cigarette 
Sales Act. As amended, date in 
effect: 10 November 2018 (3) 
Provisions of the Act include the following bans:
-  EN&NNDS use where smoking is prohibited, including enclosed public spaces, workplaces, restaurants 
and bars, and vehicles when an individual under the age of 16 is present (there are exemptions for some 
hotel rooms and private residences);
- sale and supply to minors (under 19);
- sales of EN&NNDS wherever tobacco sales are banned; and 
- indoor and outdoor advertising and promotional materials, even within vape shops.
Newfoundland and 
Labrador
Smoke-Free Environment Act (as 
amended) (4), Tobacco and Vapour 
Products Control Act (as amended) 
(5). Date in effect: 17 October 2018 
The following are banned: 
- sale to minors;
- sale wherever tobacco sales are banned;
- POS promotion, products and promotional materials (cannot be visible inside or outside the shop);
- restrictions on signage inside shops; and
- vape shops are allowed to operate if the only business conducted is the sale of vaping products.
Treatment: treats EN&NNDS the same as combustible tobacco cigarettes, prohibiting the use of EN&NNDS 
in any place to which the public customarily has access, including workplaces, private clubs, licensed 
restaurants, bus shelters, and health-care and educational facilities.
Young people: prohibits the use of EN&NNDS in motor vehicles when occupied by a person under the age 
of 16 and prohibits the sale of EN&NNDS and other vaping products to persons under the age of 19.
Communications and advertising: there currently are no restrictions on EN&NNDS advertising. Vape shops 
can provide consumers with testimonials and health information regarding vaping.
Province Applicable law Main provisions
Nova Scotia Smoke-free Places Act (amended) 
(6) and Tobacco Access Act 
(amended) (7). Date in effect: 31 
May 2015
The following are banned:
-  EN&NNDS use where smoking is prohibited, including enclosed public spaces, workplaces, education and 
recreation facilities, restaurants and bars, and vehicles when an individual under the age of 19 is present;
- sale and supply to minors (under 19 years);
- possession by minors;
- sale in pharmacies;
- requirement to display age-restriction signage; and
- POS promotion, except inside vape shops.
Ontario Electronic Cigarettes Act, 2015, 
replaced by Smoke-Free Ontario 
Act, 2017 (last amended 2019) (8)
The following are banned:
-  EN&NNDS use where smoking is prohibited, including enclosed public place and workplaces, group 
living facilities, public vehicles or vehicles used in the course of employment while carrying two or more 
employees (there are exceptions for guest rooms in hotels and designated areas in residential facilities);
- sale and supply to minors (under 19);
- supply or offer to supply health-care facilities and pharmacies;
- sale wherever tobacco sales are banned (regulatory authority to make some exemptions);
-  promotion outdoors, at POS (only signage showing price and availability allowed), and premises to which 
children are permitted access; and
- display visible to children in any place or premises in which tobacco or tobacco-related products are sold.
Quebec Tobacco Control Act. Date in 
effect: 26 November 2015 (9)
Under the law, the following are banned:
-  EN&NNDS use where smoking is prohibited, including enclosed public spaces, workplaces, educational and 
recreational facilities, restaurants and bars, and vehicles when an individual under the age of 16 is present;
- sale and supply to minors;
- sale wherever tobacco sales are banned; and
- outdoor signage restricted, shops are only allowed to show availability and price.
All prohibitions that apply to tobacco promotion also apply to EN&NNDS.
The ban on flavours in cigarettes does not apply to e-liquids.
Prince Edward
Island
Tobacco and Electronic Smoking 
Device Sales and Access Act (10) 
and regulations (11); in effect 1 
October 2015
The following are banned:
-  EN&NNDS use where smoking is prohibited, including enclosed public spaces, workplaces, education and 
recreation facilities, restaurants and bars, and vehicles when an individual under the age of 19 is present;
- sale and supply to minors and purchase by minors under the age of 19;
- sale where tobacco sale is banned;
- POS promotion and promotion visible from outside retail premises; 
- vape shops can only display e-cigarettes if individuals under the age of 19 are not permitted; and
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The World Health Organization (WHO) is a specialized agency of the United Nations created 
in 1948 with the primary responsibility for international health matters and public health. 
The WHO Regional Office for Europe is one of six regional offices throughout the world, each 
with its own programme geared to the particular health conditions of the countries it serves.
Member States
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
North Macedonia
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
